share_log

港股异动丨信达生物涨超8% 获瑞银看高至61.4港元

Gelonghui Finance ·  Nov 20 01:21

格隆汇11月20日|信达生物(1801.HK)一度涨8.5%,报38.95港元,截至目前成交额放大至6.2亿港元。瑞银称,信达商业化能力强劲,加上GLP-1料加大在减肥及二型糖尿病市场,重申“买入”评级,目标价由60.7港元上调1.2%至61.4港元。(格隆汇)

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment